Unfortunately, in many regions, G6PD testing is unavailable so the practitioner treating vivax malaria is faced with a dilemma—to give radical cure “at risk,” or to err on the side of safety and not give it. The gene discussed is G6PD; the disease is Plasmodium vivax malaria.